Anteris Technologies develops the DurAVR THV System, a heart valve for patients with aortic stenosis, for cardiologists and surgeons. AVR reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | Barclays | Initiated | Hold | |
| Aug 14 | Cantor Fitzgerald | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in AVR in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVR is in one of them and how their past AVR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AVR in an article yet. Here's the latest on the wider market.
About Anteris Technologies Global
Anteris Technologies is a structural heart company based in Eagan, Minnesota. Its main product is the DurAVR THV System, a single piece transcatheter heart valve for patients with aortic stenosis, a narrowing of the aortic valve. The valve is delivered with a balloon expandable system and is intended for use by heart specialists and surgeons who treat these patients. The DurAVR is not yet approved for commercial sale in the United States or Europe and is being studied in clinical trials.
- Headquarters
- Eagan, MN